Therapeutic efficacy of topical olopatadine 0.1% versus ketotifen fumarate in allergic conjunctivitis | [Pakistan Armed Forces Medical Journal • 2022]

Author(s):

1. Farooq Ul Abidin: Armed Forces Institute of Opthamology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

2. Muhammad Haroon Sarfraz: POF Hospital Wah Pakistan

3. Hassaan Javaid: Combined Military Hospital Peshawar/National University of Medical Sciences (NUMS) Pakistan

4. Asfandyar Khan: Armed Forces Institute of Opthamology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

5. Summaya Khan: HITEC Institute of Medical Sciences, Taxila/National University of Medical Sciences (NUMS) Pakistan

6. Haroon Javaid: HITEC Institute of Medical Sciences, Taxila/National University of Medical Sciences (NUMS) Pakistan

Abstract:

Objective: To compare the therapeutic efficacy of topical Olopatadine 0.1% versus Ketotifen Fumarate among the patients diagnosed with allergic conjunctivitis at Armed forces institute of ophthalmology. Study Design: Prospective comparative study. Place and Duration of Study: Armed forces Institute of Ophthalmology, Rawalpindi, from Jan 2020 to Jan 2021. Methodology: Patients diagnosed with allergic conjunctivitis by consultant ophthalmologist fulfilling the exclusion/inclusion criteria were included in the study. They were divided into two groups by block randomization with group A receiving Olopatadine 0.1%, while group B just received the Ketotifen Fumarate. Symptoms were assessed on a symptom severity score upon diagnosis before the start of medication and then after 72 hours of treatment by a different consultant ophthalmologist who was unaware of the group of patients. Results: A total of 100 patients were included in each group. The mean age of the study participants was 30.944 ± 3.349 years. 148 (74%) patients were males while 52 (26%) were females. The difference in mean score of symptoms in group A was 5.76 ± 1.39 while in group B was 3.33 ± 2.51. Application of t-test revealed that topical Olopatadine 0.1% was superior to Ketotifen Fumarate in reducing the symptoms of acute allergic conjunctivitis on the third day of treatment (p-value<0.001). Conclusion: Seasonal allergic conjunctivitis was the commonest type of allergic conjunctivitis seen in our study participants. Topical Olopatadine 0.1% emerged as a better treatment option when compared to Ketotifen Fumarate for immediate management of acute allergic conjunctivitis among patients managed at a tertiary care ophthalmology hospital.

Page(s): 16-19

DOI: 10.51253/pafmj.v72i1.6324

Published: Journal: Pakistan Armed Forces Medical Journal, Volume: 72, Issue: 1, Year: 2022

Keywords:

Efficacy , Allergic conjunctivitis , Ketotifen fumarate , Olopatadine 01

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views